Skip to main content
Top
Published in: Pituitary 3/2012

01-09-2012

Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation

Authors: Luis V. Syro, Jamie L. Sundsbak, Bernd W. Scheithauer, Rodrigo A. Toledo, Mauricio Camargo, Christina M. Heyer, Tomoko Sekiya, Humberto Uribe, Jorge I. Escobar, Martin Vasquez, Fabio Rotondo, Sergio P. A. Toledo, Kalman Kovacs, Eva Horvath, Dusica Babovic-Vuksanovic, Peter C. Harris

Published in: Pituitary | Issue 3/2012

Login to get access

Abstract

A 39-year-old woman with autosomal dominant polycystic kidney disease (ADPKD) presented with acromegaly and a pituitary macroadenoma. There was a family history of this renal disorder. She had undergone surgery for pituitary adenoma 6 years prior. Physical examination disclosed bitemporal hemianopsia and elevation of both basal growth hormone (GH) 106 ng/mL (normal 0–5) and insulin-like growth factor (IGF-1) 811 ng/mL (normal 48–255) blood levels. A magnetic resonance imaging scan disclosed a 3.0 cm sellar and suprasellar mass with both optic chiasm compression and left cavernous sinus invasion. Pathologic, cytogenetic, molecular and in silico analysis was undertaken. Histologic, immunohistochemical and ultrastructural studies of the lesion disclosed a sparsely granulated somatotroph adenoma. Standard chromosome analysis on the blood sample showed no abnormality. Sequence analysis of the coding regions of PKD1 and PKD2 employing DNA from both peripheral leukocytes and the tumor revealed the most common PKD1 mutation, 5014_5015delAG. Analysis of the entire SSTR5 gene disclosed the variant c.142C>A (p.L48M, rs4988483) in the heterozygous state in both blood and tumor, while no pathogenic mutations were noted in the MEN1, AIP, p27Kip1 and SSTR2 genes. To our knowledge, this is the fourth reported case of a GH-producing pituitary adenoma associated with ADPKD, but the first subjected to extensive morphological, ultrastructural, cytogenetic and molecular studies. The physical proximity of the PKD1 and SSTR5 genes on chromosome 16 suggests a causal relationship between ADPKD and somatotroph adenoma.
Literature
2.
go back to reference Torres VE, Harris PC (2009) Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 76(2):149–168PubMedCrossRef Torres VE, Harris PC (2009) Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 76(2):149–168PubMedCrossRef
3.
go back to reference Melmed S (2006) Medical progress: acromegaly. N Eng J Med 355(24):2558–2573CrossRef Melmed S (2006) Medical progress: acromegaly. N Eng J Med 355(24):2558–2573CrossRef
5.
go back to reference Fajfr R, Muller B, Diem P (2002) Hypophyseal incidentaloma in a patient with autosomal dominant polycystic kidney disease. Praxis 91(25–26):1123–1126PubMedCrossRef Fajfr R, Muller B, Diem P (2002) Hypophyseal incidentaloma in a patient with autosomal dominant polycystic kidney disease. Praxis 91(25–26):1123–1126PubMedCrossRef
7.
go back to reference Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, Bennett WM, Meyers CM, Walker DL, Bae K, Zhang QJ, Thompson PA, Miller JP, Harris PC (2007) Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 18(7):2143–2216. doi:10.1681/ASN.2006121387 PubMedCrossRef Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, Bennett WM, Meyers CM, Walker DL, Bae K, Zhang QJ, Thompson PA, Miller JP, Harris PC (2007) Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 18(7):2143–2216. doi:10.​1681/​ASN.​2006121387 PubMedCrossRef
8.
go back to reference Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, van’t Hoff WG, Niaudet P, Torres VE, Harris PC (2009) Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 75(8):848–855. doi:10.1038/ki.2008.686 PubMedCrossRef Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, van’t Hoff WG, Niaudet P, Torres VE, Harris PC (2009) Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 75(8):848–855. doi:10.​1038/​ki.​2008.​686 PubMedCrossRef
9.
go back to reference Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, Fend F, Graw J, Atkinson MJ (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 103(42):15558–15563. doi:10.1073/pnas.0603877103 PubMedCrossRef Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, Fend F, Graw J, Atkinson MJ (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 103(42):15558–15563. doi:10.​1073/​pnas.​0603877103 PubMedCrossRef
10.
go back to reference Toledo RA, Lourenco DM Jr, Liberman B, Cunha-Neto MB, Cavalcanti MG, Moyses CB, Toledo SP, Dahia PL (2007) Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J Clin Endocrinol Metab 92(5):1934–1937. doi:10.1210/jc.2006-2394 PubMedCrossRef Toledo RA, Lourenco DM Jr, Liberman B, Cunha-Neto MB, Cavalcanti MG, Moyses CB, Toledo SP, Dahia PL (2007) Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J Clin Endocrinol Metab 92(5):1934–1937. doi:10.​1210/​jc.​2006-2394 PubMedCrossRef
11.
go back to reference Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, Gundogdu S, De Menis E, Makinen MJ, Launonen V, Karhu A, Aaltonen LA (2006) Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312(5777):1228–1230. doi:10.1126/science.1126100 PubMedCrossRef Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, Gundogdu S, De Menis E, Makinen MJ, Launonen V, Karhu A, Aaltonen LA (2006) Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312(5777):1228–1230. doi:10.​1126/​science.​1126100 PubMedCrossRef
12.
go back to reference Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, Remuzzi G, Epstein FH (2005) Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 68(1):206–216PubMedCrossRef Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, Remuzzi G, Epstein FH (2005) Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 68(1):206–216PubMedCrossRef
15.
go back to reference Reisine T, Bell GI (1995) Molecular biology of somatostatin receptors. Endocr Rev 16(4):427–442PubMed Reisine T, Bell GI (1995) Molecular biology of somatostatin receptors. Endocr Rev 16(4):427–442PubMed
16.
go back to reference Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, Melmed S (1997) Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 99(4):789–798PubMedCrossRef Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, Melmed S (1997) Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 99(4):789–798PubMedCrossRef
17.
go back to reference Filopanti M, Ronchi C, Ballare E, Bondioni S, Lania AG, Losa M, Gelmini S, Peri A, Orlando C, Beck-Peccoz P, Spada A (2005) Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J Clin Endocrinol Metab 90(8):4824–4828PubMedCrossRef Filopanti M, Ronchi C, Ballare E, Bondioni S, Lania AG, Losa M, Gelmini S, Peri A, Orlando C, Beck-Peccoz P, Spada A (2005) Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J Clin Endocrinol Metab 90(8):4824–4828PubMedCrossRef
18.
go back to reference Greenman Y, Melmed S (1994) Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79(3):724–729PubMedCrossRef Greenman Y, Melmed S (1994) Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79(3):724–729PubMedCrossRef
20.
go back to reference Tulipano G, Bonfanti C, Milani G, Billeci B, Bollati A, Cozzi R, Maira G, Murphy WA, Poiesi C, Turazzi S, Giustina A (2001) Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology 73(5):344–351PubMedCrossRef Tulipano G, Bonfanti C, Milani G, Billeci B, Bollati A, Cozzi R, Maira G, Murphy WA, Poiesi C, Turazzi S, Giustina A (2001) Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology 73(5):344–351PubMedCrossRef
22.
go back to reference Taboada GF, Luque RM, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR (2007) Quantitative analysis of somatostatin receptor subtype (SSTR1–5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156(1):65–74. doi:10.1530/eje.1.02313 PubMedCrossRef Taboada GF, Luque RM, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR (2007) Quantitative analysis of somatostatin receptor subtype (SSTR1–5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156(1):65–74. doi:10.​1530/​eje.​1.​02313 PubMedCrossRef
23.
go back to reference van der Hoek J, Lamberts SW, Hofland LJ (2007) Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur J Endocrinol 156(Suppl 1):S45–S51. doi:10.1530/eje.1.02350 PubMedCrossRef van der Hoek J, Lamberts SW, Hofland LJ (2007) Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur J Endocrinol 156(Suppl 1):S45–S51. doi:10.​1530/​eje.​1.​02350 PubMedCrossRef
24.
go back to reference Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509–1517PubMedCrossRef Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509–1517PubMedCrossRef
25.
go back to reference Bronstein MD (2006) Acromegaly molecular expression of somatostatin receptor subtypes and treatment outcome. Frontiers Horm Res 35:129–134CrossRef Bronstein MD (2006) Acromegaly molecular expression of somatostatin receptor subtypes and treatment outcome. Frontiers Horm Res 35:129–134CrossRef
26.
go back to reference Casarini AP, Jallad RS, Pinto EM, Soares IC, Nonogaki S, Giannella-Neto D, Musolino NR, Alves VA, Bronstein MD (2009) Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 12(4):297–303. doi:10.1007/s11102-009-0175-1 PubMedCrossRef Casarini AP, Jallad RS, Pinto EM, Soares IC, Nonogaki S, Giannella-Neto D, Musolino NR, Alves VA, Bronstein MD (2009) Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 12(4):297–303. doi:10.​1007/​s11102-009-0175-1 PubMedCrossRef
27.
go back to reference van der Lely AJ, de Herder WW, Lamberts SW (1999) New medical treatment for acromegaly. Pituitary 2(1):89–92PubMedCrossRef van der Lely AJ, de Herder WW, Lamberts SW (1999) New medical treatment for acromegaly. Pituitary 2(1):89–92PubMedCrossRef
28.
go back to reference Vitale G, Pivonello R, Ferone D, De Martino MC, Auriemma RS, Caraglia M, Abbruzzese A, Lombardi G, Colao A (2004) The role of somatostatin receptors in the medical treatment of acromegaly. Dig Liver Dis 36(Suppl 1):S55–S59PubMedCrossRef Vitale G, Pivonello R, Ferone D, De Martino MC, Auriemma RS, Caraglia M, Abbruzzese A, Lombardi G, Colao A (2004) The role of somatostatin receptors in the medical treatment of acromegaly. Dig Liver Dis 36(Suppl 1):S55–S59PubMedCrossRef
29.
go back to reference Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, Spada A (2001) Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 86(8):3809–3814PubMedCrossRef Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, Spada A (2001) Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 86(8):3809–3814PubMedCrossRef
30.
go back to reference Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, Ruggenenti P (2010) Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 5(5):783–789. doi:10.2215/CJN.05380709 PubMedCrossRef Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, Ruggenenti P (2010) Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 5(5):783–789. doi:10.​2215/​CJN.​05380709 PubMedCrossRef
31.
go back to reference Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR 3rd, Rossetti S, Harris PC, LaRusso NF, Torres VE (2010) Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 21(6):1052–1061. doi:10.1681/ASN.2009121291 PubMedCrossRef Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR 3rd, Rossetti S, Harris PC, LaRusso NF, Torres VE (2010) Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 21(6):1052–1061. doi:10.​1681/​ASN.​2009121291 PubMedCrossRef
32.
go back to reference van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP (2009) Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 137(5):1661–1668. doi:10.1053/j.gastro.2009.07.052 e1661–e1662PubMedCrossRef van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP (2009) Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 137(5):1661–1668. doi:10.​1053/​j.​gastro.​2009.​07.​052 e1661–e1662PubMedCrossRef
33.
go back to reference Parker E, Newby LJ, Sharpe CC, Rossetti S, Streets AJ, Harris PC, O’Hare MJ, Ong AC (2007) Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system. Kidney Int 72(2):157–165. doi:10.1038/sj.ki.5002229 PubMedCrossRef Parker E, Newby LJ, Sharpe CC, Rossetti S, Streets AJ, Harris PC, O’Hare MJ, Ong AC (2007) Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system. Kidney Int 72(2):157–165. doi:10.​1038/​sj.​ki.​5002229 PubMedCrossRef
34.
go back to reference Manara R, Maffei P, Citton V, Rizzati S, Bommarito G, Ermani M, Albano I, Della Puppa A, Carollo C, Pavesi G, Scanarini M, Ceccato F, Sicolo N, Mantero F, Scaroni C, Martini C (2011) Increased rate of intracranial saccular aneurysms in acromegaly: an MR angiography study and review of the literature. J Clin Endocrinol Metab 96(5):1292–1300. doi:10.1210/jc.2010-2721 PubMedCrossRef Manara R, Maffei P, Citton V, Rizzati S, Bommarito G, Ermani M, Albano I, Della Puppa A, Carollo C, Pavesi G, Scanarini M, Ceccato F, Sicolo N, Mantero F, Scaroni C, Martini C (2011) Increased rate of intracranial saccular aneurysms in acromegaly: an MR angiography study and review of the literature. J Clin Endocrinol Metab 96(5):1292–1300. doi:10.​1210/​jc.​2010-2721 PubMedCrossRef
35.
go back to reference Sandford R, Sgotto B, Burn T, Brenner S (1996) The tuberin (TSC2), autosomal dominant polycystic kidney disease (PKD1), and somatostatin type V receptor (SSTR5) genes form a synteny group in the Fugu genome. Genomics 38(1):84–86. doi:10.1006/geno.1996.0596 PubMedCrossRef Sandford R, Sgotto B, Burn T, Brenner S (1996) The tuberin (TSC2), autosomal dominant polycystic kidney disease (PKD1), and somatostatin type V receptor (SSTR5) genes form a synteny group in the Fugu genome. Genomics 38(1):84–86. doi:10.​1006/​geno.​1996.​0596 PubMedCrossRef
36.
go back to reference Johansson M, McKay JD, Wiklund F, Rinaldi S, Hallmans G, Balter K, Adami HO, Gronberg H, Stattin P, Kaaks R (2009) Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 18(5):1644–1650. doi:10.1158/1055-9965.EPI-08-0893 PubMedCrossRef Johansson M, McKay JD, Wiklund F, Rinaldi S, Hallmans G, Balter K, Adami HO, Gronberg H, Stattin P, Kaaks R (2009) Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 18(5):1644–1650. doi:10.​1158/​1055-9965.​EPI-08-0893 PubMedCrossRef
37.
go back to reference Nyegaard M, Borglum AD, Bruun TG, Collier DA, Russ C, Mors O, Ewald H, Kruse TA (2002) Novel polymorphisms in the somatostatin receptor 5 (SSTR5) gene associated with bipolar affective disorder. Mol Psychiatry 7(7):745–754. doi:10.1038/sj.mp.4001049 PubMedCrossRef Nyegaard M, Borglum AD, Bruun TG, Collier DA, Russ C, Mors O, Ewald H, Kruse TA (2002) Novel polymorphisms in the somatostatin receptor 5 (SSTR5) gene associated with bipolar affective disorder. Mol Psychiatry 7(7):745–754. doi:10.​1038/​sj.​mp.​4001049 PubMedCrossRef
38.
go back to reference Li D, Tanaka M, Brunicardi FC, Fisher WE, Gibbs RA, Gingras MC (2011) Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival. Cancer. doi:10.1002/cncr.25858 Li D, Tanaka M, Brunicardi FC, Fisher WE, Gibbs RA, Gingras MC (2011) Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival. Cancer. doi:10.​1002/​cncr.​25858
Metadata
Title
Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation
Authors
Luis V. Syro
Jamie L. Sundsbak
Bernd W. Scheithauer
Rodrigo A. Toledo
Mauricio Camargo
Christina M. Heyer
Tomoko Sekiya
Humberto Uribe
Jorge I. Escobar
Martin Vasquez
Fabio Rotondo
Sergio P. A. Toledo
Kalman Kovacs
Eva Horvath
Dusica Babovic-Vuksanovic
Peter C. Harris
Publication date
01-09-2012
Publisher
Springer US
Published in
Pituitary / Issue 3/2012
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-011-0325-0

Other articles of this Issue 3/2012

Pituitary 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.